The future of RNAi with Arrowhead’s Chris Anzalone on The BioCentury Show

Arrowhead Pharmaceuticals CEO Chris Anzalone lays out his view of RNAi's future on The BioCentury Show, arguing siRNA beats ASOs for pure gene silencing on durability, knockdown depth and safety, while ASOs retain value for exon skipping and broader tissue access. He frames delivery beyond the liver, into CNS, adipose, lung, muscle and eye, as the key to scaling the platform.